Using PARP Inhibitors in Frontline Maintenance Therapy of Ovarian Cancer | Clinical Consult

Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.

Thomas Herzog, MD, reviews the statistics of ovarian cancer in the United States in 2020 including survival rates and types of tumors.

Insight on the importance of germline testing and HRD status in ovarian cancer as well as who should be tested.

Using maintenance therapy for the management of patients with ovarian cancer and NCCN guideline recommendations with PARP inhibitors.

A review of the MOA of PARP inhibitors and the differences between the agents including efficacy, dosing, safety, and tolerability.

Current frontline maintenance options for treatment of ovarian cancer and the use of PARP inhibitors as seen in the SOLO-1 trial.

A review of the PRIMA trial regarding patients with HRD (homologous recombination deficiency) in ovarian cancer.

A review of the PAOLA-1 trial exploring the use of olaparib with bevacizumab vs bevacizumab alone for the treatment of ovarian cancer.

Determining which agents to use when approaching frontline treatment of maintenance therapy in ovarian cancer.

Thomas Herzog, MD, evaluates the use of PARP inhibitors if a patient with ovarian cancer relapses after having been on a PARP inhibitor.

The future of treatment and challenges for the field of ovarian cancer.